Bunitrolol

In today's world, Bunitrolol has become a topic of interest to many. Whether due to its historical relevance, its impact on today's society or simply its popularity among different groups, Bunitrolol has captured the attention of people of all ages and backgrounds. In this article, we will deeply explore the many facets of Bunitrolol and discuss its importance in the current context. From its origins to its evolution over time, including its influence on various areas of daily life, we will dive into a detailed analysis that will allow us to fully understand the importance of Bunitrolol today.

Bunitrolol
Names
IUPAC name
2-benzonitrile
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
UNII
  • InChI=1S/C14H20N2O2/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15/h4-7,12,16-17H,9-10H2,1-3H3
    Key: VCVQSRCYSKKPBA-UHFFFAOYSA-N
  • InChI=1/C14H20N2O2/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15/h4-7,12,16-17H,9-10H2,1-3H3
    Key: VCVQSRCYSKKPBA-UHFFFAOYAU
  • CC(C)(C)NCC(COC1=CC=CC=C1C#N)O
Properties
C14H20N2O2
Molar mass 248.326 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).

Bunitrolol is a beta-adrenergic antagonist.[1]

Synthesis

2-Hydroxybenzonitrile (1) is treated with epichlorohydrin and sodium hydroxide to give the epoxide (2). Addition of tert-butylamine completes the synthesis of bunitrolol.[2]

See also

References

  1. ^ Haddad, S; Poulin, P; Funk, C (2010). "Extrapolating in vitro metabolic interactions to isolated perfused liver: Predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine". Journal of Pharmaceutical Sciences. 99 (10): 4406–26. doi:10.1002/jps.22136. PMID 20310018.
  2. ^ Herbert Koppe, Albrecht Engelhardt, Karl Zeile, U.S. patent 3,940,489 (1976 to Boehringer Ingelheim Gmbh).
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.